Corning Jerry KN046 treated non-small cell lung cancer Phase III clinically completed the first case of patients.

ENREACH-LUNG-01 is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study of the efficacy and safety of KN046 combined platinum-containing chemotherapy in patients with late-stage non-removable or metastasis squamous non-small cell lung cancer. It is planned to recruit approximately 500 patients at approximately 60 research centres, with the IRC's disease-free progressity survival (PFS) as the primary endpoint, with lifetime and PFS2 as secondary endpoints.
ENREACH-LUNG-01 study is based on phase II clinical studies of KN046 combined chemotherapy to treat non-small cell lung cancer, and details of the study will be presented at an academic conference in 2021.
lung cancer is the most common cancer-related cause of death worldwide, with about 750,000 new cases of lung cancer in China each year.
non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, 30% of which are lung squamous cancers, and about half of patients are diagnosed with advanced stages of the disease.
Immunological co-treatment is a breakthrough in the field of lung cancer treatment in recent years, the long-term survival benefits of dual immunotherapy drag-off effect is obvious, PD-L1 low-expression population also has good efficacy, but toxicity problems to a certain extent limit the clinical application of dual immunological joint other standard treatment, so the development of safer dual-specific antibody immuno-combined other standard treatment options, further improve patient survival benefits is clinically unsolt needs.
.